Late toxicity-related symptoms and fraction dose affect decision regret among patients receiving adjuvant radiotherapy for head and neck cancer.
Mümtaz Ali KöksalLeonard SaurDavide ScafaGustavo R SarriaChristina LeitzenChristopher SchmeelFrederick FarSebastian StriethFrank A GiordanoPublished in: Head & neck (2022)
Based on these findings, we recommended that patients with head and neck cancer undergoing adjuvant radiation receive psychosocial support and adequate treatment of late toxicity-related symptoms. When confronted with different therapeutic options, radiotherapy with a higher single fraction dose (i.e., hypofractionation) may be preferred due to its association with lower decision regret.